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Abstract 
Aims: To investigate whether vascular endothelial growth factor B (VEGF‑B) improves myocardial survival and cardiac 
stem cell (CSC) function in the ischemia–reperfusion (I/R) heart and promotes CSC mobilization and angiogenesis.
Methods and results: One hour after myocardial ischemia and infarction, rats were treated with recombinant 
human VEGF‑B protein following 24 h or 7 days of myocardial reperfusion. Twenty‑four hours after myocardial I/R, 
VEGF‑B increased pAkt and Bcl‑2 levels, reduced p‑p38MAPK, LC3‑II/I, beclin‑1, CK, CK‑MB and cTnt levels, triggered 
cardiomyocyte protection against I/R‑induced autophagy and apoptosis, and contributed to the decrease of infarc‑
tion size and the improvement of heart function during I/R. Simultaneously, an in vitro hypoxia‑reoxygenation 
(H/R)‑induced H9c2 cardiomyocyte injury model was used to mimic I/R injury model in vivo; in this model, VEGF‑B 
decreased LDH release, blocked H/R‑induced apoptosis by inhibiting cell autophagy, and these special effects could 
be abolished by the autophagy inducer, rapamycin. Mechanistically, VEGF‑B markedly activated the Akt signaling 
pathway while slightly inhibiting p38MAPK, leading to the blockade of cell autophagy and thus protecting cardio‑
myocyte from H/R‑induced activation of the intrinsic apoptotic pathway. Seven days after I/R, VEGF‑B induced the 
expression of SDF‑1α and HGF, resulting in the massive mobilization and homing of c‑Kit positive cells, triggering 
further angiogenesis and vasculogenesis in the infracted heart and contributing to the improvement of I/R heart 
function.
Conclusion: VEGF‑B could contribute to a favorable short‑ and long‑term prognosis for I/R via the dual manipulation 
of cardiomyocytes and CSCs.
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Background
Ischemic heart disease (IHD) is the leading cause of death 
in the modern world. Myocardial infarction (MI) is usu-
ally initiated by myocardial ischemia resulting from the 
narrowing of coronary arteries due to atherosclerosis. At 
the clinical level, a number of cardiovascular intervention 
techniques, such as percutaneous coronary intervention 
(PCI) and cardiac bypass surgery, have been developed to 
restore myocardial perfusion [1]. Reperfusion occurs as 
a result of these interventions (particularly PCI); in short 
term, intervention should overcome ischemia–reperfusion 
injury (I/R), while in the long term, vascular restenosis 
should be effectively prevented via the activation of angio-
genesis and vasculogenesis. However, the most effective 
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The VEGF family of archetypal angiogenic growth 
factors consists of five secreted dimeric glycoprotein 
growth factors in mammals: VEGF (or VEGF-A), VEGF-
B, VEGF-C, VEGF-D and PlGF (placenta growth fac-
tor) [2]. Although VEGF-mediated angiogenesis plays a 
critical role in the repair of ischemia/infarction, which is 
characterized by reduced blood supply to the heart [3, 4], 
until recently, VEGF-B was an exception to the family’s 
classical role in promoting angiogenesis [5, 6]. VEGF-B 
levels are highest in high metabolic tissues, such as the 
myocardium, skeletal muscle and adipose tissue [7, 8]. 
The absence of VEGF-B has been reported to lead to the 
decreased expression of fatty acid (FA) transport proteins 
in endothelial cells, which is associated with reduced 
lipid droplets in skeletal muscle and cardiomyocytes and 
improved insulin resistance in diabetes models [9–11]. 
VEGF-B is markedly down-regulated in the infarcted 
heart [12–14]. The over-expression of VEGF-B improved 
cardiac contractility in rats after experimental MI [15]. 
However, it is unknown whether VEGF-B plays a role 
in short- and long-term prognosis following myocardial 
ischemia for the development of heart failure.
In our previous study, cardiac stem cells (CSC), which 
are characterized by their migratory capabilities and 
potential for differentiating into cardiomyocytes and vas-
cular cells, showed traits of VEGFR1 expression, were 
partly involved in VEGF-A-induced CSC migration, and 
contributed to the repair of the infarcted heart by induc-
ing angiogenesis [3]. In addition to protecting cardiomy-
ocytes, VEGF-B strongly induced myocardium-specific 
angiogenesis and arteriogenesis through VEGFR1 [5, 11, 
15] and partly contributed to the involvement of endothe-
lial cells in angiogenesis [11]. Of interest, CSCs are 
directly involved in the formation of the large coronary 
arteries [16]; thus, they predict the evolution of ischemic 
cardiomyopathy following revascularization [17]. At pre-
sent, the relationship between VEGF-B-induced angio-
genesis and CSCs during the process of myocardial 
ischemia or infarction, particularly in long-term I/R, is 
unknown. Angiogenic cytokine therapy has been widely 
regarded as an attractive approach for treating ischemic 
heart disease and for preventing vascular restenosis fol-
lowing cardiovascular intervention [1, 2, 4]. Therefore, 
we hypothesize that VEGF-B plays a pivotal role in the 
short- and long-term prognosis of myocardial I/R via the 
dual manipulation of cardiomyocytes and CSCs.
Methods
All animal experiments were performed according to 
the Guide for the Care and Use of Laboratory Animals 
recommended by the US National Institutes of Health. 
All protocols for animal studies were permitted by the 
Institutional Animal Care and Use Committee of Hubei 
University of Medicine.
Heart ischemia–reperfusion injury model
To observe whether VEGF-B protects against myocardial 
I/R injury in  vivo, a rat model of myocardial I/R injury 
was established. Male Sprague–Dawley rats (240–280 g) 
were obtained from the Experimental Animal Center at 
Hubei University of Medicine and housed at an appro-
priate temperature (25 °C) with relative humidity (55 %), 
a fixed 12-h light/dark cycle and free access to food and 
water. The animals were randomly divided into four 
groups, as follows: a sham-operated group, an I/R injury 
group (I/R), a VEGF-B (1.0  μg/kg) group and a VEGF-
B (10  μg/kg) group. The in  vivo doses of VEGF-B were 
selected according to a previous study [18]. VEGF-B 
solution 200–300 μL (1.0 or 10 μg/mL) was injected with 
a 30-gauge tuberculin syringe into four sites (approxi-
mately 50–75  μL per site) into each I/R heart; volumes 
were determined according to the rat’s body weight. Two 
injection sites were in the myocardium bordering the 
ischemic area, and two were within the ischemic area. 
The animals were anesthetized with ketamine (50  mg/
kg, ip) and xylazine (10 mg/kg, ip) and ventilated during 
left anterior descending coronary artery (LAD) ligation 
using a Colombus ventilator (HX-300, Taimeng Instru-
ments, China). Surgery was performed under sterile con-
ditions. The LAD was ligated for 1 h, and then opened for 
treatment with VEGF-B (local injection of the left myo-
cardium, four sites at 50 μL per site) for 24 h or 7 days 
of reperfusion. In the sham-operation group, the rats 
underwent identical surgery but without ligation of the 
coronary artery. Buprenorphine hydrochloride (0.05 mg/
kg, sc) was administered one time after the procedure.
Measurement of creatine kinase (CK), CK‑MB activity 
and cardiac troponin T (cTnT)
This procedure was described in detail elsewhere [19]. 
Briefly, 24  h after treatment, blood samples were cen-
trifuged at 3500 rpm for 15 min at 4 °C; then the serum 
was collected. Subsequently, according to a handbook 
of experimental operations, CK activity (JianCheng Bio-
engineering Institute, Nanjing, China), CK-MB activity 
(Rapidbio, USA) and cardiac troponin T (cTnT) (Rapid-
bio, USA) levels, as enzymatic diagnostic indexes of myo-
cardial injury, were detected and analyzed.
Hemodynamic measurement
Hemodynamic measurement was performed as described 
previously [20]. Briefly, after 24 h of reperfusion, the ani-
mals were anesthetized with ketamine (50 mg/kg, ip) and 
xylazine (10  mg/kg, ip), and the left carotid artery was 
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exposed. A catheter filled with heparinized (10  U/ml) 
saline solution was connected to a pressure transducer 
(Chengdu Taimeng Technology Co., Ltd., China) and 
then advanced into the left ventricle to record ventricu-
lar pressure for 15 min. Hemodynamic parameters were 
monitored simultaneously and recorded using Biological 
signal acquisition system BL-420S (Chengdu Taimeng 
Technology Co., Ltd., China).
Histological measurement
Twenty-four hours after reperfusion, the hearts were 
removed and washed with K-H buffer at room tem-
perature for 3  min, frozen at −20  °C for 1  h and trans-
verse-sectioned into five parts (thickness, 2–5  mm). 
The sections were then incubated in 1  % 2, 3, 5-triphe-
nyltetrazolium chloride (TTC, Sigma, USA) at 37  °C for 
15  min. The infarcted myocardium was not stained by 
the TTC and appeared white in color; meanwhile, the 
non-ischemic myocardium was stained by the TTC and 
appeared brick-red in color. The infarction size was cal-
culated by multiplying the planimetered areas by the slice 
thickness. The infarction size was expressed as the per-
centage of the left ventricular size of each heart.
Cardiomyocyte apoptosis assay in vivo
To analyze cardiomyocyte apoptosis, 24 h after reperfu-
sion, the hearts were removed, fixed in 4 % paraformalde-
hyde and embedded in an optimum cutting temperature 
compound (Fisher Scientific). Serial transverse Sections 
(5 μm) were cut across the longitudinal axis of the heart 
and mounted on slides. After a brief washing in phos-
phate-buffered saline (PBS), the heart sections were 
incubated in a blocking buffer [PBS containing 1 % fetal 
calf serum (FCS) and 0.1 % Triton X-100] at room tem-
perature for 1 h. Cardiomyocyte apoptosis was detected 
using the methods described in the manual of the In-
Situ Apoptosis Detection Kit (MM_NF-S7165#, Mil-
lipore, UEA). Five fields from each section (n = 3) were 
randomly selected. The number of apoptotic cells was 
counted manually by two pathologists, who were una-
ware of the experimental design. The rate of apopto-
sis was calculated as the percentage of all cells per high 
power field (HPF; 400×).
Immunostaining
Seven days after I/R, the heart tissues were fixed in 4 % 
paraformaldehyde and embedded in optimum cutting 
temperature compound (Fisher Scientific). Serial trans-
verse Sections (5  μm) were cut across the longitudinal 
axis of the heart and washed with phosphate-buffered 
saline (PBS). The heart sections were then incubated in 
a blocking buffer at room temperature for 1 h. The sec-
tions were incubated in antibodies (diluted 1:250 in 
blocking buffer) at 4 °C overnight for primary antibodies 
and at room temperature for 2 h for secondary antibod-
ies. The primary antibodies used were mouse anti-rat 
vWF VIII, rabbit anti-rat a-SMA (Santa Cruz) and anti-
rat c-kit (Abcam). The secondary antibodies were FITC-
conjugated anti-rabbit IgG, FITC-conjugated anti-rat 
IgG, and FITC-conjugated anti-mouse IgG (Santa Cruz) 
[3]. Images of c-Kit positive cells or vessels were acquired 
under microscopy (magnification, 400×) for five random 
fields in the infarcted area of each transverse slice for all 
three groups. The number of c-Kit positive cells or ves-
sels in the infarcted areas was counted manually by two 
pathologists who were unaware of the experimental 
design and are presented as the mean of c-Kit positive 
cells or blood vessels per unit area (0.2 mm2).
Culture of H9c2 rat cardiomyocytes
The rat embryonic ventricular myocardial cell line H9c2 
was purchased from the Cell Bank of the Chinese Acad-
emy of Sciences (Shanghai, China). H9c2 cells were cul-
tured as described previously [19].
Hypoxia‑reoxygenation of H9c2 Cells
The in  vitro hypoxia-reoxygenation of H9c2 cells 
occurred as described previously [19]. In brief, H9c2 
cells were treated with or without VEGF-B (20  ng/ml, 
Peprotech, USA) in EBSS after H9c2 cells culture under 
low-oxygen conditions (95 % N2  +   5 % CO2) for 6 h in 
a humidified hypoxia chamber (Stem Cell Technology, 
USA). The in  vitro doses of VEGF-B (0.1, 1, 10, 20 and 
50  ng/ml) were determined as described in detail else-
where [21]. After hypoxic incubation, the medium was 
replaced with 15 % FBS medium under normoxic condi-
tions (95 % air  +  5 % CO2) for reoxygenation for 3 h.
Cell apoptosis assay in vitro
Cell apoptosis was determined as described previously 
[19]. According to the cell apoptosis protocol, H9c2 cells 
were resuspended in 500 µl binding buffer after washing 
and then incubated with Annexin V solution for 3 min, 
followed by PI solution (Bender MedSystems, Austria) 
for 15 min. The apoptotic cells were analyzed with flow 
cytometry.
Lactate dehydrogenase (LDH) release
The LDH level is an indicator of cellular injury [19]. 
The LDH release was measured using commercial kits 
(JianCheng Bioengineering Institute, China).
Cell autophagy assay
H9c2 cells were cultured on a chamber slide to 50–60 % 
confluence. The cells were transfected with Ad-mRFP-
GFP-LC3-I/II (MOI: 100, Hanbio, Co, China) for 48  h 
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and then treated with VEGF-B (10 ng/ml) according the 
protocol for the hypoxia-reoxygenation of H9c2 Cells.
Western blot
The H9c2 cells or heart tissues were lysed in RIPA 
buffer, and 30  µg of proteins were separated in a 12  % 
SDS–PAGE gel and transferred onto a nitrocellulose 
membrane (Millipore). The membrane was rinsed with 
Tris-buffered saline (TBS) containing 0.1  % Tween-
20 (TBST) and blocked with 5  % fat free milk in TBS 
at room temperature for 1  h. The membrane was then 
incubated with anti-Akt, anti-phospho-Akt, anti-Bcl-2, 
anti-Bax, anti-beclin1, anti-p38MAPK, anti-ERK1/2, 
anti-pp38MAPK, anti-pERK1/2 (Cell Signaling Technol-
ogy, 1:500), anti-SDF-1α, anti-HGF (Santa Cruz) or anti-
α-Tubulin antibody (Sigma, 1:5000) and then incubated 
with horseradish peroxidase-conjugated secondary anti-
bodies (1:10,000 dilution; Santa Cruz). The immunoblots 
were detected using enhanced chemiluminescence reac-
tion (Amersham Pharmacia Biotech) and measured with 
densitometry.
Statistical analysis
All data are expressed as mean  ±  SD. The parameters 
of two groups were compared using the unpaired t test. 
The parameters of more than two groups were compared 
using one-way analysis of variance. P values <0.05 were 
considered statistically significant.
Results
VEGF‑B reduced infarct size and improved heart function
To observe the effect of VEGF-B on heart I/R injury 
in  vivo, we performed I/R experiments that mimic 
therapeutic reperfusion in human patients. Rat hearts 
were subjected to ischemia by ligating the LAD for 1 h, 
followed by reperfusion for 24  h to assess the effect of 
VEGF-B on myocardial infarct size and heart function 
in an I/R model in vivo. One-percent TTC staining was 
used to evaluate the infarct size of rat hearts exposed 
to reperfusion with or without VEGF-B treatment. The 
results showed that 1.0 and 10 μg/kg VEGF-B treatment 
significantly reduced the infarct size in  vivo compared 
with the I/R group. Furthermore, the 10  μg/kg VEGF-
B group showed a greater decrease in the infarct size 
compared with the 1.0 μg/kg VEGF-B group (Fig. 1a, b). 
In line with the change in infarct size, the left ventricle 
function of the heart in both VEGF-B groups was signifi-
cantly improved compared with the I/R group. Further-
more, the higher dose of VEGF-B had a much greater 
effect on increasing LVSP and ±dp/dtmax and decreas-
ing LVEDP compared with the lower dose of VEGF-B 
(Fig. 1c–f ).
VEGF‑B suppressed CK, CK‑MB activity, and cTnT levels 
on heart I/R injury
To monitor myocardial damage, CK, CK-MB, and cTnT 
activity was detected to evaluate myocardial injury. The 
results showed that CK, CK-MB, and cTnT activity were 
obviously increased in the I/R group compared with the 
sham group (Additional file  1: Figure S1A–D). Interest-
ingly, compared with the I/R group, the VEGF-B groups 
all had significantly reduced CK, CK-MB activity and 
cTnT levels. Furthermore, high-dose VEGF-B had bet-
ter protective effects against heart I/R (Additional file 1: 
Figure S1A–C). These data suggest that VEGF-B inhibits 
I/R-mediated myocardial injury.
VEGF‑B inhibits I/R‑mediated cardiocyte apoptosis in vivo
To further assess the potential protective mechanism of 
VEGF-B in heart I/R injury, cardiomyocyte apoptosis, a 
classical marker of myocardial I/R damage, was examined 
after VEGF-B treatment. We found that VEGF-B sig-
nificantly decreased the apoptosis rate of cardiocytes in 
the in vivo I/R model (Fig. 2a, b). Bcl-2/Bax, two typical 
indicators of cardiocyte apoptosis, were used to evalu-
ate the effect of VEGF-B on myocardium exposed to I/R. 
The results showed that Bcl-2 expression was obviously 
induced and Bax expression was significantly decreased 
in VEGF-B-treated hearts compared with the I/R group 
(P  <  0.05). Finally, Bcl-2/Bax regulation was generally 
involved in multiple signaling pathways, such as PI3K/
Akt, ERK1/2 and p38MAPK, et  al. [22]. The changes in 
nonphosphorylated and phosphorylated Akt, ERK1/2 
and p38MAPK were analyzed and compared with 
those of the I/R group. Akt, ERK1/2 and p38MAPK and 
pERK1/2 levels were not markedly increased (Addi-
tional file  1: Figure S2), but pAkt levels were obviously 
increased in both the VEGF-B (1.0) and VEGF-B (10) 
group (Fig.  2c–e). Meanwhile, p-p38MAPK levels were 
decreased in the two VEGF-B groups. Furthermore, the 
higher dose of VEGF-B had better benefits for increasing 
pAkt levels and decreasing p-ERK1/2 and p-p38MAPK 
levels.
In addition, because VEGF-B is a newly identified met-
abolic factor [23] associated with cell autophagy, we also 
examined changes in LC3-II/I, an indicator of autophagy. 
We found that the LC3-II/I rates were increased in I/R 
group compared to with the sham group and that com-
pared with the I/R group, the two VEGF-B treatment 
groups showed decreased LC3-II/I rates, and the higher 
dose of VEGF-B had a better effect on reducing LC3- II/I 
rates (Fig. 2c, i).
These data suggest that VEGF-B could prevent I/R-
mediated cardiocyte autophagy and apoptosis associated 
with the PI3K/Akt and p38MAPK signaling pathways.
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VEGF‑B reversed the changes in H/R‑induced H9c2 cell 
apoptosis in vitro
To develop a detailed description of the role and mecha-
nism of VEGF-B in I/R injury, an in  vitro H/R-induced 
H9c2 cell damage model was established to mimic the 
in vivo myocardial I/R model. DAPI staining showed that 
H/R injury caused significant apoptosis in H9c2 cells, as 
shown by condensed nuclei, an indicator of apoptosis. 
However, VEGF-B restored H9c2 nuclei to their normal 
morphology (Fig.  3a). The appearance of phosphatidyl-
serine (PS) in the outer leaflet of the phospholipid bilayer 
without a disruption in membrane integrity is one of 
the earliest characteristics of apoptotic cells [20]. Flow 
cytometry assay was used to evaluate the changes in cell 
apoptosis using Annexin V/PI staining, which indicates 
PS production. As Fig. 4b shows, I/R induced H9c2 cell 
apoptosis. However, VEGF-B attenuated the number 
of Annexin V/PI-positive cells, suggesting that VEGF-B 
inhibited H/R-induced apoptosis (Fig. 3b). Furthermore, 
the protective effects of VEGF-B on H9c2 cells exposed 
to H/R showed dose-dependent characteristics (Fig. 3c).
LDH release is an indicator of cellular injury [22]. 
Compared with untreated cells, LDH levels were mark-
edly increased by H/R injury. VEGF-B treatment, 
Fig. 1 VEGF‑B improved heart function in a myocardium I/R model. a TTC‑stained myocardium 24 h after reperfusion. The white arrows indicate the 
infarct area of heart. b Infarction size in each group. The infarct size was expressed as a percentage of the left ventricular size for each heart. *P < 0.01 
vs. sham group; # P < 0.01 vs. I/R group, n = 6. c Typical image of heart function. 24 h after reperfusion, LV function was measured as described in 
the “Methods” section. LVSP‑left ventricle systolic pressure (d); LVEDP‑left ventricle end‑diastolic pressure (e); ±dp/dtmax‑rate of the rise or fall of left 
ventricular pressure (g and h). *P < 0.01 vs. sham group; #P < 0.05 vs. I/R group; &P < 0.05 vs. VEGF‑B (1.0) group, n = 6
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however, decreased H/R-induced LDH release (Fig.  3d). 
Meanwhile, H/R obviously induced Bax expression and 
decreased Bcl-2 expression in H9c2 cells, and VEGF-B 
treatment significantly increased Bcl-2 expression while 
reducing Bax expression in H/R-injured H9c2 cells in a 
dose-dependent manner (Fig.  3e–h). These data sug-
gest that VEGF-B is able to protect cardiomyocytes from 
H/R-induced injury in a dose-dependent manner.
VEGF‑B regulated cell apoptosis in vitro
A recent publication indicates that apoptosis is medi-
ated by numerous signaling pathways, such as PI3K/Akt, 
ERK/1/2 and p38 MAPK [23]. To test whether these mech-
anisms apply to VEGF-B-induced myocardium protection, 
we used VEGF-B to stimulate cardiomyocytes before H/R 
injury. We found that VEGF-B obviously enhanced pAkt, 
slightly increased pERK1/2, and decreased p-p38MAPK 
without affecting their expression (Additional file  1: Fig-
ure S3) in a dose-dependent manner (Fig. 4a–d). To con-
firm whether these signaling molecules were involved 
in VEGF-B-mediated anti-apoptosis, special inhibitors 
were used to assess the relationship between them. The 
results showed that the ERK1/2 inhibitor PD98059 did 
not obviously abolish the anti-apoptotic effect of VEGF-B, 
but the p38MPAK inhibitor SB203580 and the PI3K spe-
cific inhibitor LY294002 obviously blocked it (Fig.  4e, f ), 
suggesting that VEGF-B prevents apoptosis in cardiomyo-
cytes through PI3K/Akt and p38MAPK signaling.
VEGF‑B inhibited H/R‑induced H9c2 cell apoptosis 
through the regulation of Bcl‑2/Bax expression mediated 
by PI3K/Akt signaling
Because the cell survival regulators Bcl-2 and Bax are 
regulated by PI3K/Akt signaling [23] and VEGF-B had a 
regulatory effect on Bcl-2/Bax expression (Fig. 3e–h), we 
examined whether VEGF-B-mediated Bcl-2/Bax regu-
lation was involved in PI3K/Akt signaling. As shown 
in Additional file  1: Figure S4A, VEGF-B markedly 
increased Bcl-2 while decreasing Bax expression, sug-
gesting that VEGF-B prevents apoptosis in H9c2 cells 
by readjusting the expression and ratio of Bcl-2 and Bax 
(Additional file 1: Figure S4A). LY294002 blocked VEGF-
B-mediated Bcl-2 and Bax expression (Additional file  1: 
Figure S4A, 4D–4F), suggesting that VEGF-B regulates 
Bcl-2/Bax expression through the PI3K/Akt signaling 
pathway.
Fig. 2 VEGF‑B inhibited I/R‑mediated cardiocyte apoptosis in vivo. a A typical image of cardiomyocyte apoptosis in the heart I/R model was 
detected and analyzed using the TUNNEL method. Red fluorescence apoptotic cells; Blue fluorescence cell nucleus. b Quantitative analysis of the 
cell apoptosis rate in HPF. *P < 0.01 vs. sham group; #P < 0.05 vs. I/R group, n = 6. c Bcl‑2, pAkt, Bax, pERK1, pp38MAPK and LC3‑II/I expression was 
detected using western blot, as described in the Materials and methods section (c), and quantified using normalization to a‑tubulin (d–i). *P < 0.01 
vs. sham group; #P < 0.05 vs. I/R group, n = 6
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VEGF‑B inhibited I/R‑induced autophagy in a 
dose‑dependent manner
VEGF-B is a newly identified metabolic factor [24] 
that could be associated with cell autophagy. To deter-
mine whether VEGF-B affected autophagy, as shown 
in Fig. 5a, H/R increased the expression of autophagy-
related proteins in H9c2 cells. VEGF-B reduced the 
levels of autophagy-related proteins and the ratio of 
LC3-II/I seen on western blot analysis (Fig. 5a, b). The 
GFP-RFP-LC3 adenovirus (Ad-mRFP-GFP-LC3) system 
was further used to confirm the induction of autophagy 
using punctate forms, which represent autophagosome 
formation [25]. As Fig.  3c shows, after infection with 
Ad-mRFP-GFP-LC3, we observed the successful intro-
duction of this adenovirus and both fluorescent pro-
teins. In addition to accumulation of LC3, there were 
more red puncta in the H/R-induced H9c2 cells than 
in the control cells. Furthermore, VEGF-B markedly 
decreased the number of red puncta in a dose-depend-
ent manner. These results further confirmed the induc-
tion of autolysosome formations in the H/R model, 
indicating that VEGF-B mediated an anti-autophagy 
flux in H9c2 cells.
VEGF‑B inhibited H9c2 cell apoptosis by inhibiting 
H/R‑induced autophagy
To further explore the involvement of VEGF-B in H9c2 
cell apoptosis in the H/R-induced autophagy model, 
the autophagy inducer rapamycin and the autophagy 
inhibitor chloroquine were used to determine whether 
VEGF-B’s effect on autophagy involved H9c2 cell apop-
tosis. As Fig.  6a and c show, rapamycin reversed the 
Fig. 3 VEGF‑B restored H/R‑induced alterations of H9C2 cell morphology and cell apoptosis. a Cell apoptosis was detected using DAPI. b Cell apop‑
tosis was detected using Annexin V/PI staining, n = 6. c Quantitative analysis of cell apoptosis in (b). *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 
vs. H/R‑treated cells; @P < 0.05 vs. 0.1 ng/ml VEGF‑B‑treated cells; $P < 0.05 vs. 1.0 ng/ml VEGF‑B‑treated cells; &P < 0.05 vs. 10 ng/ml VEGF‑B‑treated 
cells; ^P > 0.05 vs. 20 ng/ml VEGF‑B‑treated cells, n = 6. d VEGF‑B reduced LDH levels. *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 vs. H/R‑treated 
cells; @P < 0.05 vs. 0.1 ng/ml VEGF‑B‑treated cells; $P < 0.05 vs. 1.0 ng/ml VEGF‑B‑treated cells; &P < 0.05 vs. 10 ng/ml VEGF‑B‑treated cells; ^P > 0.05 
vs. 20 ng/ml VEGF‑B‑treated cells, n = 6. e Bcl‑2 and Bax expression was detected using western blot, as described in the Materials and methods 
section (e), and quantified via normalization to a‑tubulin (f–h). *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 vs. H/R‑treated cells; $P < 0.05 vs. 1.0 ng/
ml VEGF‑B‑treated cells; &P < 0.05 vs. 10 ng/ml VEGF‑B‑treated cells, n = 6
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VEGF-B-mediated anti-apoptosis effects, the VEGF-B-
mediated anti-autophagy effects and the LC3-II/I rates 
in the H/R model (Fig.  6d, e), suggesting that VEGF-
B-mediated anti-autophagy plays a critical role in the 
protective effects of VEGF-B in H9c2 cells under H/R 
conditions. Additionally, chloroquine enhanced the 
VEGF-B-mediated anti-autophagy and anti-apoptosis 
effects in H/R-induced cell injury. These data demon-
strate that VEGF-B could inhibit H/R-induced cell apop-
tosis by blocking autophagy.
VEGF‑B inhibited autophagy‑mediated H9c2 cell apoptosis
Because the p38MAPK and PI3K/Akt signaling pathways 
play important roles in both apoptosis and autophagy [26, 
27], the PI3K-specific inhibitor LY294002, an autophagy 
inducer, was used to observe the effects of VEGF-B on 
H9c2 cells under H/R conditions [27]. As Fig. 7a, b show, 
the expression of autophagy-related proteins and LC3-
II/I rates increased and the autophagy flux (shown in 
red) was enhanced in H/R-induced injury of H9c2 cells. 
VEGF-B reduced the levels of autophagy-related proteins 
Fig. 4 VEGF‑B inhibited H/R‑induced H9c2 cell apoptosis in vitro. a pAkt, pERK1 and pp38MAPK expression was detected using western blot, as 
described in the “Methods” section (b), and quantified via normalization to a‑tubulin (b–d). *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 vs. H/R‑
treated cells; @P < 0.05 vs. 0.1 ng/ml VEGF‑B‑treated cells; $P < 0.05 vs. 1.0 ng/ml VEGF‑B‑treated cells; &P < 0.05 vs. 10 ng/ml VEGF‑B‑treated cells; 
^P < 0.05 vs. 20 ng/ml VEGF‑B‑treated cells, n = 6. e Cell apoptosis was detected using Annexin V/PI staining, n = 6. f Quantitative analysis of cell 
apoptosis in (e). *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 vs. H/R‑treated cells; @P > 0.05 vs. H/R‑treated cells; $P > 0.05 vs. H/R‑treated cells; 
&P < 0.05 vs. H/R‑treated cells; ^P < 0.05 vs. 20 ng/ml VEGF‑B‑treated cells, n = 6
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and LC3-II/I rates, and the special effects of VEGF-B on 
autophagy could be abolished by the PI3K-specific inhibi-
tor LY294002, suggesting that VEGF-B inhibited autophagy 
via PI3K/Akt signaling (Fig. 7a–d). Interestingly, the special 
effects of VEGF-B on anti-autophagy could not be abolished 
by the ERK1/2 inhibitor PD98059 but could be abolished by 
the p38MPAK inhibitor SB203580 (Additional file 1: Figure 
S5), which was consistent with the finding that PD98059 
and not SB203580 inversed VEGF-B-mediated anti-apop-
tosis (Fig. 5e). These results imply that VEGF-B can inhibit 
autophagy-mediated H9c2 cell apoptosis by regulating the 
PI3K/Akt, ERK1/2 and p38MPAK signaling pathways.
VEGF‑B promoted CSC mobilization, angiogenesis 
and improved heart function
To determine whether VEGF-B can stimulate the mobi-
lization of CSC in infarcted hearts, we locally injected 
VEGF-B into the heart prior to LAD ligation, isolated 
the infarcted myocardium 7 days after I/R, and detected 
the presence of CSC by immunostaining stem cell mark-
ers for c-kit. A large number of c-kit-positive cells were 
observed in the VEGF-B-treated myocardium (Fig. 8a, b). 
Because SDF-1α and HGF play important roles in CSC 
mobilization in the infarcted myocardium, we detected 
SDF-1α and HGF expression in the infarcted heart using 
western blotting and found that SDF-1α and HGF expres-
sion obviously increased in infarcted myocardium treated 
with VEGF-B in a dose-dependent manner (Fig. 8c–e).
CSCs are closely related to the differentiation of vas-
cular cells, such as endothelial cells and vascular smooth 
muscle cells [16]. Consequently, 7  days after VEGF-B 
treatment, angiogenesis in the I/R heart was evaluated 
according to microvessel density and artery vessel den-
sity, as indicated by the expression of vWF VIII, a mature 
endothelial cell marker, and α-SMA, a vascular smooth 
muscle cell marker, respectively (Fig. 8f ). We found that 
Fig. 5 VEGF‑B inhibited H/R‑induced autophagy. a LC3‑II/I expression was detected using western blot, as described in the “Methods” section (a), 
and quantified via normalization to a‑tubulin (b). *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 vs. H/R‑treated cells; @P < 0.05 vs. 0.1 ng/ml VEGF‑
B‑treated cells; $P < 0.05 vs. 1.0 ng/ml VEGF‑B‑treated cells; &P < 0.05 vs. 10 ng/ml VEGF‑B‑treated cells; ^P < 0.05 vs. 20 ng/ml VEGF‑B‑treated cells, 
n = 3. c Representative images showing LC3 staining in different groups of H9c2 cells infected with Ad‑GFP‑RFP‑LC3 for 48 h
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VEGF-B significantly induced blood vessel formation 
in dose-dependent manner, resulting in increased ves-
sel density (Fig. 8g). An in vitro tube formation assay of 
SDF-1α receptor/CXCR4 inhibitor AMD3100 and the 
HGF receptor c-Met inhibitor SU11274 were used to 
further confirm whether VEGF-B-induced angiogen-
esis involved SDF-1α and HGF (Additional file  2). As 
shown in Additional file 1: Figure S6, CM-VB induced the 
formation of new tubes from c-kit-positive cells in vitro, 
and the effect could be partly abolished by AMD3100 or 
SU11274. These data demonstrate that VEGF-B induced 
angiogenesis mediated by c-kit-positive cells in infarcted 
myocardium by activating SDF-1α and HGF signaling.
Furthermore, VEGF-B treatment significantly 
improved the function of the left ventricle of the heart, 
and the higher dose of VEGF-B had a much greater 
Fig. 6 VEGF‑B inhibited H9c2 cell apoptosis by inhibiting H/R‑induced autophagy. a Cell apoptosis was detected using Annexin V/PI staining, 
n = 6. b Quantitative analysis of cell apoptosis in (a). c Representative images showing LC3 staining in different groups of H9c2 cells infected with 
Ad‑GFP‑RFP‑LC3 for 48 h. c LC3‑II/I expression was detected using western blot, as described in the “Methods” section (a), and quantified using 
normalization to a‑tubulin (d). *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 vs. H/R‑treated cells; @P < 0.05 vs. 20 ng/ml VEGF‑B‑treated cells; $P > 
0.05 vs. H/R‑treated cells, n = 6
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effect on increasing LVSP and ±dp/dtmax and decreasing 
LVEDP compared with the lower dose (Additional file 1: 
Figure S7A–D).
Discussion
In this study, we demonstrate for the first time that 
human VEGF-B protein promotes cardiomyocyte sur-
vival by activating the PI3K/Akt/Bcl-2/Beclin1 signaling 
pathway after short-term I/R and activates CSC mobili-
zation and angiogenesis via the induced expression of 
SDF-1 and HGF in infarcted heart after long-term I/R. 
We also demonstrated improvement in cardiac function 
following VEGF-B treatment.
Previous studies demonstrated that VEGF-B had a 
protective role in the heart after experimental M) or 
angiotensin II-induced heart failure in rats [5, 28–31]. 
The transgene (TG), adenoviral-mediated (Ad) or adeno-
associated virus (AAV) expression of VEGF-B used in 
the animal model of MI or heart failure is strong and 
long-term, and the safety and controllability of these vec-
tors are controversial for practical application [32]. Clini-
cally, human VEGF-B protein should be more far more 
acceptable to patients. Recombinant human VEGF-B 
protein were therefore used in the present study to deter-
mine the beneficial effects of VEGF-B on cardiomyocyte 
protection, CSC mobilization, angiogenesis and cardiac 
function of I/R rats.
A recent study shows that VEGF-B induces compensa-
tory hypertrophy and preserves cardiac function through 
VEGFR-1 activation of cardiomyocytes after MI [15]. 
Pathways downstream of VEGF-B/VEGFR1, including 
the Akt/mTORC1 and ERK1/2, p38MAPK pathways, 
which are known to be associated with cardiomyocyte 
growth and arteriogenesis, were activated in the heart 
[31, 33, 34]. Consequently, VEGF-B’s protective effect 
on cardiomyocytes is dependent on PI3K/Akt signaling, 
which is in line with the pro-survival function of VEGF-
A [35, 36]. The anti-apoptotic effects of VEGF-B may be 
Fig. 7 VEGF‑B inhibited H/R‑induced autophagy through PI3/Akt signaling. a LC3‑II/I expression was detected using western blot, as described 
in the “Methods” section (a), and quantified via normalization to a‑tubulin (b, c). *P < 0.05 vs. 15 % FBS‑treated cells; #P < 0.05 vs. H/R‑treated cells; 
@P < 0.05 vs. 20 ng/ml VEGF‑B‑treated cells; $P > 0.05 vs. H/R‑treated cells, n = 6. d Representative images showing LC3 staining in different groups 
of H9c2 cells infected with Ad‑GFP‑RFP‑LC3 for 48 h, n = 6
Page 12 of 14Li et al. J Transl Med  (2016) 14:116 
interpreted using the PI3K inhibitor LY294002 and the 
ERK1/2 inhibitor PD98059 to abolish its roles. The unex-
pected outcome is that the p38MAPK blocker SB203580 
inversed the anti-apoptotic effects of VEGF-B on H/R- 
induced H9c2 cells, while VEGF-B decreased the levels 
of p-p38MAPK induced by H/R, indicating that the levels 
of p-p38MAPK were related to apoptosis regulation in 
VEGF-B-mediated cardiomyocyte protection.
Notably, several studies have suggested that p38 MAPKs 
regulated distinct phases of autophagy. p38MAPK can 
elicit autophagy via Beclin1 [26]. Interestingly, Bcl-
2, a downstream regulator of PI3K/Akt, can inhibit 
Beclin1-dependent autophagy, and Beclin1-mediated 
autophagy activation during reperfusion is associated 
with Bcl-2 down-regulation [37]. Notably, Bcl-2 protein 
is also involved in the regulation of apoptosis. Decreased 
expression of Bcl-2 may contribute to apoptotic cell death 
[36]. In the present study, VEGF-B increased Bcl-2 protein 
levels and inhibited H9c2 cell apoptosis and autophagy 
while decreasing the levels of p-p38 MAPKs and Beclin1. 
Additionally, the specific effects could be abolished by the 
PI3K-Akt inhibitor LY294002 and the p38 MAPK inhibi-
tor SB203580, demonstrating that VEGF-B prevented 
the detrimental effects of autophagy and apoptosis by 
Fig. 8 VEGF‑B promoted CSC mobilization and angiogenesis and improved heart function. a, b The typical picture of c‑kit‑positive CSCs in I/R 
hearts after VEGF‑B treatment. Blue, DAPI‑labeled nucleus; green, c‑kit positive. b The number of c‑kit‑positive CSCs in I/R hearts was counted, and 
statistical analyses were performed. The bar represents 25 µm. #P = 0.05 vs. I/R group; *P < 0.05 vs. VEGF‑B (1.0) group, n = 6. c–e SDF‑1α and HGF 
expression was detected using western blot, as described in the “Methods” section (c), and quantified via normalization to a‑tubulin (d, e). n = 6. 
#P < 0.05 vs. I/R group; *P < 0.01. vs. VEGF‑B (1.0) group; &P < 0.01. vs. sham group. f Typical picture of vWF VIII and a‑SMA immunostaining for the 
analysis of vessel density in the infarcted heart. g Quantitative analysis of vessel density, as indicated. #P < 0.05 vs. I/R group; *P < 0.01. vs. VEGF‑B 
(1.0) group, n = 6
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controlling the balance between PI3K-Akt and p38 MAPK 
signaling.
The PI3K/Akt pathway is also linked to increased car-
diomyocyte proliferation [38], and the over-expression 
of VEGF-B could directly induce the proliferation of resi-
dent c-kit-positive CSC in an angiotensin II-induced heart 
failure model [5]. In our study, we found that VEGF-B 
increased the number of c-kit-positive CSCs, which are 
associated with the activation of the PI3K/Akt pathway, in 
the I/R heart. In addition, MSC releases paracrine factors 
such as VEGF, SDF1α, and HGF. As a functional conse-
quence, a conditioned medium of MSCs has a migratory 
effect on cardiac resident c-kit-positive CSCs [3]. CSCs, 
which express c-Kit, MDR1, and/or Sca-1 markers, are 
self-renewing, clonogenic and multipotent in  vitro and 
differentiate into cardiomyocytes, smooth muscle cells, 
and endothelial cells in vivo. A recent study showed that 
endogenous c-kit-positive cells produce few new cardio-
myocytes and mainly generate cardiac endothelial cells at 
functionally significant levels within the heart during heart 
development, ischemia and infarction states, suggesting 
that c-kit-positive cells contribute to heart repair through 
enhanced cardiac angiogenesis [39]. Our previous study 
showed that VEGF-A directly and indirectly promoted 
CSC mobilization in the infarcted heart via the SDF-1α/
CXCR4 axis [3, 20]. In the present study, VEGF-B protein 
injection clearly increased the number of resident c-kit-
positive CSCs in the I/R heart while inducing the expres-
sion of SDF-1α and HGF, triggering CSC mobilization, 
and inducing angiogenesis and vasculogenesis, leading 
to improved cardiac function in the I/R heart. Therefore, 
VEGF-B could repair the injured heart by activating the 
angiogenesis mediated by CSCs after long-term I/R.
Conclusion
Taken together, the results of the present study suggest 
that VEGF-B can improve the short- and long-term prog-
nosis of I/R via the dual manipulation of cardiomyocyte 
protection and CSCs.
Additional files
Additional file 1. VEGF‑B suppressed CK, CK‑MB and cTnT in I/R model 
of heart in rat in vivo. The levels of total Akt, ERK1 and p38MAPK were not 
obviously altered in I/R model of heart in rat in vivo and in H/R model 
of H9c2 cells in vitro after VEGF‑B treatment. However, VEGF‑B inhibited 
H/R‑induced H9c2 cell apoptosis through up‑regulating Bcl2 and down‑
regulating Bax expression, these specific effects could be abolished by 
PI3K/Akt blocker. And the representative images results showing LC3 
changes were shown after SB203580 or PD98059 treatment prior to VEGF‑
B in different groups of H9c2 cells infected with Ad‑GFP‑RFP‑LC3. More 
importantly, the long‑term effects of VEGF‑B on tube formation of c‑kit 
positive CSC in vitro and heart function in vivo were shown.
Additional file 2. Isolated c‑kit+ cells from rat hearts were cultured 
and used to evaluate the ability of tube formation of c‑Kit cells following 
stimulation of conditioned medium from H9c2 cells treated with VEGF‑B.
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